Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.

Oscar Braun, Besim Bico, Uzma Chaudhry, Henrik Wagner, Sasha Koul, Patrik Tydén, Fredrik Scherstén, Stefan Jovinge, Peter Svensson, Gustav Smith, Jesper vanderPals

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

45 Citeringar (SciVal)

Sammanfattning

Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).
Originalspråkengelska
Sidor (från-till)26-30
TidskriftThrombosis Research
Volym135
Utgåva1
DOI
StatusPublished - 2015

Ämnesklassifikation (UKÄ)

  • Kardiologi

Fingeravtryck

Utforska forskningsämnen för ”Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här